Therapy News and Research

RSS

Sheffield researchers find vital new evidence on how to reverse effects of Parkinson's mutation

Researchers from the University of Sheffield have found vital new evidence on how to target and reverse the effects caused by one of the most common genetic causes of Parkinson's.

16 Oct 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration.

15 Oct 2014

AirXpanders' AeroForm expander shows superior outcomes in patients undergoing breast reconstruction

The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system for mastectomy patients undergoing breast reconstruction, continue to show superior outcomes compared to traditional saline expanders including dramatically shorter expansion times, according to updated clinical data results presented at Plastic Surgery The Meeting, the annual scientific meeting of the American Society of Plastic Surgeons.

15 Oct 2014

Scientists create light-activated drug to help control type 2 diabetes

Scientists have created a drug for type 2 diabetes that is switched on by blue light, which they hope will improve treatment of the disease.

15 Oct 2014

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

The Mount Sinai Hospital is first in the United States to use the first and only FDA-approved, drug-coated balloon to open blocked arteries in the leg.

15 Oct 2014

Research findings point toward new therapeutic target for aggressive breast cancer

One of the first-known oncogenes has a protein partner that helps breast cancer proliferate and when it's blocked, so is the cancer, scientists report.

15 Oct 2014

Researchers identify potential cause of PPROM that accounts for 40% of pre-term births

Scientists from Queen Mary University of London and UCL (University College London) have identified what they believe could be a cause of pre-term premature rupture of the fetal membrane (PPROM), which accounts for 40 per cent of pre-term births, and is the main reason for infant death world-wide.

15 Oct 2014

New technique for treating eye cancer retinoblastoma

Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease.

14 Oct 2014

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th.

14 Oct 2014

Discovery could prolong life of people living with glioblastoma

Researchers at the University of Calgary's Hotchkiss Brain Institute and Southern Alberta Cancer Research Institute have made a discovery that could prolong the life of people living with glioblastoma – the most aggressive type of brain cancer. Samuel Weiss, PhD, Professor and Director of the HBI, and Research Assistant Professor Artee Luchman, PhD, and colleagues, published their work today in Clinical Cancer Research, which is leading researchers to start a human phase I/II clinical trial as early as Spring 2015.

14 Oct 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%.

14 Oct 2014

Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

The American Society of Anesthesiologists today presented Henrik Kehlet, M.D., Ph.D., with its 2014 Excellence in Research Award in recognition of his outstanding contributions to research which have had an important impact on anesthesiology as a medical specialty.

14 Oct 2014

Research opens door to potential new treatments for peripheral artery disease

Researchers have developed a technique to jump-start the body's systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

14 Oct 2014

Nursing home chain agrees to pay $38M to settle government poor care claims

Extendicare, which owns 150 nursing homes in 11 states and denied any wrongdoing, was accused of inappropriate billing and providing inadequate care.

14 Oct 2014

ASI treats first patient using Peregrine System Infusion Catheter

Ablative Solutions, Inc., a privately held company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it has treated the first patient in the Peregrine Study.

14 Oct 2014

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older.

14 Oct 2014

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

Cardio3 BioSciences, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announces today it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure in Switzerland.

14 Oct 2014

FDA approves new hepatitis C drug, Harvoni

Insurers and patients are decrying the cost for the new drug, nearly $95,000 for a 12-week course of treatment, which is more expensive than Gilead's other hepatitis C drug, Sovaldi. But unlike some hepatitis C treatments, Harvoni can be taken without injections usually given to hepatitis C patients.

14 Oct 2014

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

Therapy News and Research

Sheffield researchers find vital new evidence on how to reverse effects of Parkinson's mutation

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Penn Medicine announces recipients of new Basser External Research Grant Program

AirXpanders' AeroForm expander shows superior outcomes in patients undergoing breast reconstruction

Scientists create light-activated drug to help control type 2 diabetes

Mount Sinai Hospital first in nation to use drug-coated balloon to open blocked arteries in the leg

Research findings point toward new therapeutic target for aggressive breast cancer

Researchers identify potential cause of PPROM that accounts for 40% of pre-term births

New technique for treating eye cancer retinoblastoma

High doses of fish oil supplements do not reduce atrial fibrillation

Discovery could prolong life of people living with glioblastoma

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

Research opens door to potential new treatments for peripheral artery disease

Nursing home chain agrees to pay $38M to settle government poor care claims

ASI treats first patient using Peregrine System Infusion Catheter

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

C3BS receives authorization to begin CHART-1 European Phase III trial for C-Cure in Switzerland

FDA approves new hepatitis C drug, Harvoni

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News